Synthesis was expressed as cost per cured male. When the prevalence of infection exceeded 2%, LE-EIA screening was significantly more cost effective than no screening at all. Incremental costs per cured male of switching from LE-EIA to EIA screening was $2,144 at its lowest, i.e. when the prevalence of infection in males was 100%. Confirmation of positive EIA results improved the cost effectiveness of the EIA screening when the prevalence of infection in males was less than 54%.
Nevertheless, the incremental cost of switching from LE-EIA screening to EIA combined with confirmation was $2,202 per cured male at its lowest, i.e, when the prevalence of infection in males was 100%.
Compared to a 7 day course of doxycycline, a single oral dose of azithromycin administered under supervision improved the cure rates of both EIA and LE-EIA screening strategies by 15.1-16.3% and 11.2-12.0% respectively, while reducing overall costs by 5 and 9% respectively, regardless of the prevalence among males.